Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia
Clinical trial NCT02181660 · COMPLETED
Trial details
- NCT number
- NCT02181660
- Sponsor
- Astellas Pharma Inc
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-06-16
- Primary completion
- 2016-06-27
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.